These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 9349298)
1. Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral neutralization. Zibert A; Dudziak P; Schreier E; Roggendorf M Arch Virol; 1997; 142(3):523-34. PubMed ID: 9349298 [TBL] [Abstract][Full Text] [Related]
2. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Zibert A; Schreier E; Roggendorf M Virology; 1995 Apr; 208(2):653-61. PubMed ID: 7538251 [TBL] [Abstract][Full Text] [Related]
3. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus. Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211 [TBL] [Abstract][Full Text] [Related]
4. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595 [TBL] [Abstract][Full Text] [Related]
5. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392 [TBL] [Abstract][Full Text] [Related]
6. Sequence evolution and cross-reactive antibody responses to hypervariable region 1 in acute hepatitis C virus infection. Hjalmarsson S; Blomberg J; Grillner L; Pipkorn R; Allander T J Med Virol; 2001 Jun; 64(2):117-24. PubMed ID: 11360243 [TBL] [Abstract][Full Text] [Related]
7. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831 [TBL] [Abstract][Full Text] [Related]
8. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031 [TBL] [Abstract][Full Text] [Related]
9. A correlation between the heterogeneity of hypervariable region 1 of E2 glycoprotein of Hepatitis C virus (HCV) and HCV antibody profile: a case study. Kmieciak D; Biernacka-Lukanty J; Migdalski P; Turek-Plewa J; Wierzbicki A; Juszczyk J; Trzeciak WH Acta Virol; 2005; 49(2):97-103. PubMed ID: 16047736 [TBL] [Abstract][Full Text] [Related]
10. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon. Hattori M; Yoshioka K; Aiyama T; Iwata K; Terazawa Y; Ishigami M; Yano M; Kakumu S Hepatology; 1998 Jun; 27(6):1703-10. PubMed ID: 9620346 [TBL] [Abstract][Full Text] [Related]
11. Keyhole Limpet Hemocyanin-Conjugated Peptides from Hepatitis C Virus Glycoproteins Elicit Neutralizing Antibodies in BALB/c Mice. Deng K; Xu Z; Chen M; Liu X J Immunol Res; 2021; 2021():3108157. PubMed ID: 33532506 [TBL] [Abstract][Full Text] [Related]
12. Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response. Allander T; Beyene A; Jacobson SH; Grillner L; Persson MA J Infect Dis; 1997 Jan; 175(1):26-31. PubMed ID: 8985192 [TBL] [Abstract][Full Text] [Related]
13. Sequences in the hypervariable region 1 of hepatitis C virus show only minimal variability in the presence of antibodies against hypervariable region 1 during acute infection in chimpanzees. Zhou YH; Sugitani M; Esumi M Arch Virol; 2002 Oct; 147(10):1955-62. PubMed ID: 12376756 [TBL] [Abstract][Full Text] [Related]
14. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. Scarselli E; Cerino A; Esposito G; Silini E; Mondelli MU; Traboni C J Virol; 1995 Jul; 69(7):4407-12. PubMed ID: 7539508 [TBL] [Abstract][Full Text] [Related]
15. Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries. Zhai W; Davies J; Shang DZ; Chan SW; Allain JP J Viral Hepat; 1999 Mar; 6(2):115-24. PubMed ID: 10607222 [TBL] [Abstract][Full Text] [Related]
16. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. Prentoe J; Jensen TB; Meuleman P; Serre SB; Scheel TK; Leroux-Roels G; Gottwein JM; Bukh J J Virol; 2011 Mar; 85(5):2224-34. PubMed ID: 21123377 [TBL] [Abstract][Full Text] [Related]
17. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Zibert A; Meisel H; Kraas W; Schulz A; Jung G; Roggendorf M Hepatology; 1997 May; 25(5):1245-9. PubMed ID: 9141445 [TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus. Esumi M; Zhou YH; Tanoue T; Tomoguri T; Hayasaka I Vaccine; 2002 Aug; 20(25-26):3095-103. PubMed ID: 12163260 [TBL] [Abstract][Full Text] [Related]
19. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Shang D; Zhai W; Allain JP Virology; 1999 Jun; 258(2):396-405. PubMed ID: 10366577 [TBL] [Abstract][Full Text] [Related]
20. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. Bassett SE; Thomas DL; Brasky KM; Lanford RE J Virol; 1999 Feb; 73(2):1118-26. PubMed ID: 9882313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]